Enveda, a leading biotechnology company utilizing life’s chemistry to discover better medicines, today announced an investment from Sanofi, a leading healthcare company. This funding reaffirms the industry’s confidence in Enveda’s drug discovery platform and its ability to deliver differentiated medicines. Sanofi’s joining of the Series C funding round builds on Enveda’s continued success in bringing novel therapeutics inspired by evolution from discovery to clinical trials.
Enveda has made progress in building a pipeline of molecules with novel mechanisms of action that address pressing medical needs in chronic diseases.
The company also recently advanced ENV-294, a first-in-class molecule for atopic dermatitis and asthma, to clinical trials. ENV-294 can fill a major gap in the immunology and inflammation (I & I) therapeutic area by potentially providing a safe and effective oral therapy. And this funding reflects the strength of Enveda’s clinical pipeline and the broader potential of its AI-enabled drug discovery engine, redefining how we tap into nature’s chemical diversity to develop new medicines.
The commitment from Sanofi validates the growing importance of AI-based approaches to drug discovery and development and the fact that we have so much more to learn from the chemistry of living systems. And Enveda’s platform, which integrates computational methods with deep chemical and biological insights, unlocks unprecedented opportunities to develop new classes of medicines with the potential for enhanced safety, efficacy, and patient convenience.
With this funding round, Enveda is prepared to expand its clinical pipeline further in 2025, enhance its AI-driven discovery capabilities, and pioneer a new era in metabolite-driven drug development – one that delivers better medicines faster.
KEY QUOTE:
“We believe that nature holds the key to the next generation of breakthrough medicines, and we are proving that in the clinic. This investment from a global leader in immunology, is a testament to the transformative potential of our platform, our team’s execution, and the growing realization that AI can radically unlock insight into the natural world to change lives. We have beat the industry’s pace and success rate of drug discovery, providing novel medicines that we hope fill the therapeutic gaps.”
– Viswa Colluru, Ph.D., Founder and CEO of Enveda
